Friedreich共济失调疾病与市场格局 - FA是一种由单个frataxin基因突变引起的衰弱性疾病 该突变导致frataxin蛋白水平低下 进而引发多器官功能障碍 [3] - 目前市场上有一款获批的FA治疗药物omaveloxolone 但其作用靶点是Nrf2 而非疾病根源的frataxin蛋白 [3] Design Therapeutics的核心研发项目与作用机制 - 公司的核心研发项目是FA治疗项目 其关键临床试验RESTORE-FA研究正在顺利进行中 预计数据读出时间为2026年下半年 [2] - 公司针对FA的候选药物DT-216是一种异双功能基因靶向嵌合体 属于GeneTAC小分子药物 [3] - DT-216的作用机制旨在识别导致FA的GAA重复序列扩增 并上调正常的frataxin RNA转录 从而从根源上解决蛋白水平低下的问题 [3]

Design Therapeutics (NasdaqGS:DSGN) Q1 2026 Earnings call April 28, 2026 08:30 AM ET Company ParticipantsPratik Shah - CEOPratik ShahI'm Pratik Shah, Chief Executive Officer of Design Therapeutics. During this presentation, we will use forward-looking statements with regards to our business, R&D activities, and financial conditions, which are subject to known and unknown risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk fact ...

Design Therapeutics (NasdaqGS:DSGN) Q1 2026 Earnings call April 28, 2026 08:30 AM ET Company ParticipantsPratik Shah - CEOPratik ShahI'm Pratik Shah, CEO of Design Therapeutics. During this presentation, we will use forward-looking statements with regards to our business, R&D activities, and financial conditions, which are subject to known and unknown risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factor section of our mo ...